In ovarian cancer, AURKA regulates the p16 pathway through the SOX8-FOXK1 signaling axis, inhibiting cellular senescence and enhancing glucose metabolism, ultimately leading to cisplatin resistance (Sun et al., 2020). Here, FOXK1 is linked to ovarian carcinoma.